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Background
Exposure to HIV-1 does not necessarily result in infection
and progression toward disease. Discovery of individuals
who, despite multiple exposures to HIV remain unin-
fected (ESN) or do not progress toward disease (Long
term Non Progressors) (LTNP), have confidently revealed
that the better control of viral infection may be achieved
through mechanisms of natural resistance. Antibodies
(Abs) to CD4/gp120 complex have been detected in ESN,
which could be involved in HIV protection.
Materials and methods
To assess whether these Abs may also contribute to slow
HIV-disease progression, we searched for anti-CD4/gp120
complex Abs in 132 subjects, including 72 Long Term
Non Progressors (LTNP), 30 Fast Progressors, and 30
seronegative donors.
Results
We found that these antibodies are present at higher titers
in LTNP as compared to Fast Progressors (p < 0,001). In
single patients, an association between the presence of
CD4/gp120 complex antibodies and neutralizing activity
against R5 dependent strains was found. Noteworthy,
competition with soluble CD4 prevalently inhibited
binding to CD4-gp120 complex in LTNP (-46,0% [60,9–
34,8 IQR]) as compared to FP (-12,7% [33,7–5,4 IQR])(p
< 0,001), further suggesting a major contribution of anti-
complex antibodies in the anti-CD4 activity detected in
the former. As these antibodies recognize conformational
epitopes within the CD4/gp120 complex, they may be
involved in modulation of HIV entry process.
Conclusion
These antibodies could represent a marker of disease pro-
gression. Moreover, our finding could be relevant for vac-
cine design and therapeutics.
from 2006 International Meeting of The Institute of Human Virology
Baltimore, USA. 17–21 November, 2006
Published: 21 December 2006
Retrovirology 2006, 3(Suppl 1):P36 doi:10.1186/1742-4690-3-S1-P36
<supplement> <title> <p>2006 International Meeting of The Institute of Human Virology</p> </title> <note>Meeting abstracts. A single PDF containing all abstracts in this Supplement is available <a href=" http://www.biomedcentral.com/content/files/pdf/1742-4690-3-S1-full.pdf ">here</a></note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-3-S1-info.pdf</url></supplement>
© 2006 Burastero et al; licensee BioMed Central Ltd. 
